OBD, now a public AIM-listed company with global reach, was spun out from Oxford University in 2007 with the aim of translating fundamental scientific advances in 3D Genomics into a new generation of commercialized blood tests for life-changing diseases, including delivering both EpiSwitch CiRT, EpiSwitch PSE and EpiSwitch CST into the hands of doctors.
2007
OBD spun-out from Oxford University by Dr. Akoulitchev and Dr. Ramadass to translate breakthrough scientific advances into a commercialized platform technology.
2016
IPO: OBD listed on The London Stock Exchange (AIM: OBD) after raising £20M from investors.
2018
Consortium including OBD receives €4M Horizon 2020 award
2019
EpiSwitch platform selected for Prostate Cancer trial led by Imperial College London – PROSTAGRAM – evaluating novel methods of screening for prostate cancer.
OBD receives Queen’s Award for Enterprise.
2020
Nationwide COVID-19 lockdown begins in the UK.
EpiSwitch COVID-19 disease severity program launches with international partners Oregon Health & Science University (OHSU) and Boca Biolistics, laying the foundations for EpiSwitch CST by building a leading 3D genomic knowledgebase from 500+ world-wide patient samples.
OBD announces expanded strategic focus beyond biomarker discovery to the development and commercialization of life-changing clinical tests, bringing its technology pipeline rapidly into the precision medicine market.
2021
EpiSwitch CST launched in the US, an advanced blood test for understanding an individual’s risk of severe illness due to COVID-19.
EpiSwitch Explorer Array Kit launched for R&D use to enable a new level of 3D genome-wide screening, facilitated with a supply and resale partnership with Agilent® Technologies.
OBD moves into a new 24,000 sq ft tailor-made facility in Oxford with state-of-the-art lab space to support ongoing growth and the expanded strategic focus.
2022
EpiSwitch CiRT launched in the US, a transformative first-of-its-kind blood test providing guidance on whether to begin or continue treatment with an essential, widely used class of therapies: Immune Checkpoint Inhibitors.
EpiSwitch CiRT now available in the UK to private physicians considering ICI therapy for their patients.
ESMO 2022 podium presentation by Barts Cancer Centre, Pfizer, Dana-Farber Cancer Institute et al., highlights unique benefit of the EpiSwitch Platform in predicting treatment response to Pfizer’s avelumab, a leading immune checkpoint inhibitor.
New US reimbursement PLA code issued for EpiSwitch CiRT for all requests for insurance reimbursement, whether from Medicare, Medicaid or private payors.
2023
Publication of compelling results involving OBD’s technology in the PROSTAGRAM study, using blood to detect prostate cancer in an at-risk population.
OBD wins second PACT Award, to develop prognostic test for IO-related hyperprogressive disease.
Launch of EpiSwitch PSE in US and UK.
Unique PLA-CPT Code for PSE published.
2024
Opening of UK Clinical Laboratory in Oxford HQ.
Partnership with Goodbody Clinic provides UK-wide access to PSE Test.